OGT 2115 is an effective and cell-permeable heparanase inhibitor (IC50: 0.4 μM). OGT 2115 also suppresses heparan sulfate degradation activity. OGT 2115 has anti-angiogenic properties (IC50: 1 μM).

OGT 2115 obviously inhibits the invasion and migration induced by Adriamycin. Furthermore, the MTT assay results display that OGT 2115 does not decrease the anti-proliferative effect of Adriamycin. Heparanase InhibitorOGT 2115 can inhibit metastasis induced by endoplasmic reticulum (ER) stress in breast cancer cells, although not significantly. The number and rate of migrated cells are significantly reduced following the exposure of the cells to Tunicamycin + OGT 2115, compared with the control group [2].

OGT 2115 displays a plasma concentration of ~10x the heparanase IC50 following oral dosing at 20 mg/kg when administered to mice[1].

853929-59-6

C24H16BrFN2O4

495.3

OGT 2115

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years